GlassScriptPhysician profile
Ibrahim Ebada Sadek
NPI 1457672685
$14,995.05
in general payments reported to CMS, 2019-2025
66 companies · $5,275 in 2025
The $5,275 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $517 · 2022: $1,778 · 2023: $3,529 · 2024: $3,895 · 2025: $5,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,313 · Education: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,675.33 |
| Consulting Fee | $1,312.50 |
| Education | $711.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,492.29 | 2022-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $905.51 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Seagen INC. | $801.45 | 2022-2025 | Adcetris, Tivdak, Tukysa |
| Novartis Pharmaceuticals Corporation | $764.98 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $751.11 | 2021-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $727.64 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Pfizer INC. | $713.64 | 2022-2025 | |
| Celgene Corporation | $707.07 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Emd Serono, INC. | $647.51 | 2021-2025 | Bavencio |
| Incyte Corporation | $641.19 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $417.11 | 2022-2025 | |
| Janssen Biotech, INC. | $387.82 | 2022-2025 | Rybrevant, Erleada, Talvey |
| Astellas Pharma US INC | $370.41 | 2023-2025 | Vyloy, Padcev, Xospata |
| Genzyme Corporation | $369.52 | 2022-2025 | |
| Lilly USA, LLC | $297.67 | 2022-2025 | Verzenio, Retevmo, Jaypirca |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.79 | 2022-2025 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $275.44 | 2023-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $267.29 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Genentech USA, INC. | $240.87 | 2022-2025 | Tecentriq, Polivy, Venclexta |
| Glaxosmithkline, LLC. | $232.67 | 2022-2025 | Ojjaara, Blenrep, Zejula |
| Gilead Sciences, INC. | $211.22 | 2022-2025 | Trodelvy |
| Kite Pharma, INC. | $206.05 | 2022-2023 | Yescarta |
| Jazz Pharmaceuticals INC. | $183.90 | 2022-2025 | |
| Amgen INC. | $168.53 | 2022-2023 | Lumakras, Kyprolis, Blincyto |
| Cti Biopharma Corp. | $165.25 | 2022-2023 | Vonjo |
| Beigene USA, INC. | $164.30 | 2022-2025 | Brukinsa |
| Adc Therapeutics America, INC. | $161.69 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $150.70 | 2023 | Imbruvica, Epkinly |
| Alexion Pharmaceuticals, INC. | $138.21 | 2023-2024 | Ultomiris |
| Array Biopharma INC | $138.19 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Beone Medicines USA, INC. | $134.18 | 2025 | Brukinsa, Tevimbra |
| Ipsen Biopharmaceuticals, INC | $125.52 | 2022-2025 | Somatuline Depot, Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $122.57 | 2022-2025 | |
| Sobi, INC | $101.61 | 2022-2025 | |
| G1 Therapeutics, INC. | $99.66 | 2023 | Cosela |
| Pharmaessentia USA Corporation | $92.46 | 2024-2025 | Besremi |
| Puma Biotechnology, INC. | $89.02 | 2022-2025 | |
| Tempus Ai, INC | $88.46 | 2024 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.82 | 2024-2025 | Gilotrif |
| Dendreon Pharmaceuticals LLC | $84.29 | 2025 | Provenge |
| Pharmacosmos Therapeutics INC. | $83.86 | 2023-2024 | Monoferric, Cosela |
| Taiho Oncology, INC. | $80.15 | 2024-2025 | |
| Genmab U.S., INC. | $70.45 | 2024-2025 | Epkinly |
| Geron Corporation | $57.51 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $55.52 | 2022-2024 | |
| Stemline Therapeutics INC. | $55.24 | 2023-2025 | Orserdu |
| Tolmar, INC. | $51.58 | 2024-2025 | Eligard, Rubraca |
| Sun Pharmaceutical Industries INC. | $49.65 | 2022-2025 | |
| Tersera Therapeutics LLC | $48.79 | 2022-2024 | Zoladex |
| Foundation Medicine, INC. | $46.03 | 2023 | |
| Aveo Pharmaceuticals, INC. | $38.87 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $31.71 | 2023 | Empaveli |
| Karyopharm Therapeutics INC. | $31.26 | 2022-2023 | Xpovio |
| Pharmaand Gmbh | $28.56 | 2025 | Rubraca |
| Spectrum Pharmaceuticals INC. | $27.66 | 2023 | Rolvedon |
| Rigel Pharmaceuticals, INC. | $26.15 | 2024 | Tavalisse, Rezlidhia |
| Agios Pharmaceuticals, INC. | $24.69 | 2024 | Pyrukynd |
| Telix Pharmaceuticals | $22.93 | 2023 | Illuccix |
| Morphosys, US INC. | $21.83 | 2023 | Monjuvi |
| Myriad Genetic Laboratories, INC. | $21.20 | 2024 | Myrisk |
| Eusa Pharma (US) LLC | $20.11 | 2022 | |
| Novocure INC. | $19.66 | 2025 | Optune Lua (Novottf-200t) |
| Adaptive Biotechnologies Corporation | $18.69 | 2025 | Clonoseq |
| Legend Biotech USA INC. | $16.28 | 2025 | Carvykti |
| Global Blood Therapeutics, INC. | $15.46 | 2022 | |
| Kyowa Kirin, INC. | $13.60 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Sadek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.